IgA nephropathy

News

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.

News

Roche's IgAN hopeful sefaxersen passes phase 3 test

Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.

News

Otsuka's Voyxact faces rival as FDA okays Vera IgAN drug

Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgAN that will compete with Otsuka's recently-launched Voyxact.

News

Vertex chief executive Reshma Kewalramani

Vertex preps FDA filing for IgAN drug after phase 3 readout

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia.

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

Roche's IgAN hopeful sefaxersen passes phase 3 test

Otsuka's Voyxact faces rival as FDA okays Vera IgAN drug

Vertex preps FDA filing for IgAN drug after phase 3 readout

Otsuka joins IgAN market with Voyxact approval in US

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

IgA nephropathy

Editor's Picks